To the Editor Inferior vena cava (IVC) filters are used to prevent deep vein thromboses from becoming pulmonary emboli (PE). In an Editor’s Note in a recent issue of JAMA Internal Medicine, Dr Redberg argues that the absence of evidence of benefit and the definite harms of IVC filters warrants a moratorium on their use.1 This is a step away from evidence-based medicine. Admittedly, there is limited evidence of benefit, but what evidence exists is scientifically sound; the PREPIC prospective randomized study2 8-year data clearly showed a 50% decrease in PE risk after IVC filter placement. On the other hand, there are no large IVC filter studies that support the claim of an increase in clinically significant negative outcomes.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Hoffer EK. Evidence-Based Rationale for Use of Inferior Vena Cava Filters. JAMA Intern Med. 2018;178(4):573–574. doi:10.1001/jamainternmed.2018.0058
Customize your JAMA Network experience by selecting one or more topics from the list below.